Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00625586 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by MacroGenics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00625586 is a Phase 2 study that was terminated before completion, run by MacroGenics. The registered enrollment target is 2 participants.
The verdict
NCT00625586, a Phase 2 study, was terminated before completion, sponsored by MacroGenics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving RAV12 together with gemcitabine may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and best dose of monoclonal antibody RAV12 when given together with gemcitabine in treating patients with metastatic pancreatic cancer.
Interventions
- DRUG Gemcitabine
- BIOLOGICAL RAV12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-04-15 |
| Est. Completion | 2009-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00625586
The ClinicalTrials.gov registry entry for NCT00625586 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00625586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00625586 about?
NCT00625586 is a clinical study titled "Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer". RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as gemcitabine, work in differen...
What is the current status of trial NCT00625586?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2008-04-15. Estimated completion is 2009-03-18.
What interventions are being tested in trial NCT00625586?
The interventions under investigation include: Gemcitabine (DRUG), RAV12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00625586?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.